GGT与PLT比值指数对慢性乙型肝炎肝纤维化的诊断价值

摘要

Early and accurate diagnosis of hepatic fibrosis and application of antiviral therapy are the key to improving the prognosis of patients with chronic hepatitis B (CHB).Liver biopsy and transient elastography cannot be widely used for the diagnosis of hepatic fibrosis in clinical practice,and therefore,the serological diagnostic model has become a hot research topic in recent years.This article introduces a new serological diagnostic model,γ-glutamyl transpeptidase-to-platelet ratio (GPR),which has a high value in the diagnosis of hepatic fibrosis in CHB patients;however,the accuracy of GPR varies between different populations and different areas.GPR is also an excellent predictor for the prognosis of hepatitis B-associated liver cancer.It is pointed out that GPR has a promising future in the diagnosis of hepatic fibrosis in CHB patients,but due to a lack of clinical research data on GPR,further studies are needed to support its application in China.%早期、准确地诊断肝纤维化并给予抗病毒治疗是改善慢性乙型肝炎预后的关键.肝活组织检查及瞬时弹性成像技术诊断肝纤维化难以在临床普遍使用,因而血清学诊断模型成为近年的研究热点.介绍了一种新的肝纤维化血清学诊断模型GGT与PLT比值指数(GPR),其对慢性乙型肝炎肝纤维化的诊断价值较高,但GPR在不同人群、不同地区诊断的准确性存在差异.GPR也是慢性乙型肝炎相关肝细胞癌预后的良好预测指标.认为GPR用于慢性乙型肝炎肝纤维化的诊断有良好前景,但因GPR临床研究数据较少,故在我国推广应用尚需进一步的研究证实.